,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['mbc', 'breast']
destiny breast 04. this is what we will see today in the plenary at asco majority of pts had received more than three lines of therapy in the metastatic setting. this is practice changing. we now have a new standard for our pts with her2 low mbc! #asco2022 
A dedicated conference for oncology held under the theme "Access. Educate. Collaborate"